Adverse Event Reports Rising Faster Than FDA Adds Surveillance Staff
This article was originally published in The Tan Sheet
Executive Summary
Adverse event reports submitted each year have quadrupled over the last decade, and FDA expects the reports to retain their value in ensuring product safety even as more technology helps with drug safety monitoring.
You may also be interested in...
FDA’s Sentinel Likely To Outpace Traditional Post-Market Studies, But Will It Replace Them?
Pilot project for overactive bladder drug Mybretriq raises questions as to how Sentinel will affect sponsor’s risk-monitoring obligations.
AER Label Guidance Holds To Requiring Full Addresses For OTCs, Supplements
FDA is extending the deadline for serious adverse event labeling requirements for OTC drugs and dietary supplements until January 2010 because it has yet to finalize its guidance to comply with those regulations
FDA’s Authority Looks Safe From Judicial Interference Following Supreme Court Abortion Pill Arguments
The agency's and the pharma industry’s worst fears – that a potential ruling in the mifepristone case might usurp the FDA’s scientific authority and throw the stability of the US drug approval process into question – seem unlikely to materialize as the majority of the Supreme Court justices signal the Alliance for Hippocratic Medicine lacks standing to sue.